IPO Landscape: Surging SPACs and a Pandemic Boom Ahead
This report analyzes key aspects of initial public offerings for technology and life sciences companies that went public in 2020 and an outlook of the year ahead.Read More
Amanda is a recognized, focused and innovative leader in the capital markets and life sciences space.
She advises life sciences and technology companies with respect to corporate finance, SEC reporting and governance matters. Amanda has represented issuers and underwriters in a wide variety of public and private financing transactions, including initial public offerings, follow-on and secondary offerings, SPACs, at-the-market offerings, private investment in public equity (PIPEs), and preferred stock and debt financings.
Amanda also advises late-stage private companies with respect to general corporate governance and liquidity preparation and public companies on corporate and securities law compliance and disclosure matters, including corporate governance best practices, Exchange Act reporting obligations and stock exchange requirements.
Chambers USA ranks Amanda as a top capital markets lawyer. In 2022, Amanda was highlighted by The Legal 500 as among the leading lawyers in U.S. capital markets and healthcare: life sciences.
Prior to joining Fenwick, Amanda was an associate at an Am Law 100 law firm. While in law school, Amanda was associate editor for the Seattle University Law Review.
Amanda “stands out as an exceptional young attorney with great judgment, poise, 24/7 availability and extreme attention to detail.”
Chambers Global (2020) and Chambers USA (2019 – 2022) recognized Amanda as a leading lawyer in the Western United States in Capital Markets: Debt & Equity
J.D., magna cum laude
Seattle University School of Law
B.A., cum laude, Political Science and Communication
University of Washington
Admitted to practice in Washington